FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

716122004: Blinatumomab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2016. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3304745011 Blinatumomab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3304746012 Blinatumomab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
371551000195113 blinatumomab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
795371000172110 blinatumomab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
3340181001000115 Blinatumomab de Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Blinatumomab (substance) Is a Monoclonal antibody false Inferred relationship Some
Blinatumomab (substance) Is a Antineoplastic agent (substance) true Inferred relationship Some
Blinatumomab (substance) Is a Bispecific monoclonal antibody (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing blinatumomab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Blinatumomab (substance) Inferred relationship Some 1
Product containing blinatumomab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Blinatumomab (substance) Inferred relationship Some 1
Product containing only blinatumomab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Blinatumomab (substance) Inferred relationship Some 1
Product containing only blinatumomab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Blinatumomab (substance) Inferred relationship Some 1
Blinatumomab 38.5 microgram powder for solution for infusion vial The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Blinatumomab (substance) Inferred relationship Some 1
Blinatumomab 38.5 microgram powder for solution for infusion vial This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Blinatumomab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start